SAGE 241220 10.00P (SAGE241220P10000) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Dec 23 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Oct 17 06:42

NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...

Jaguar8

Oct 8 05:31

NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...

Sikander KHAN

Jul 29 08:26

Don't expect exceptional Q2 results.

$Sage Therapeutics (SAGE.US)$ Stock is good, but sentiment is negative. I don't see any significant and sustainable upside by Q3. Another 20% to 30% downside is 'Likely'
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...

Trytosaveabit

Jul 24 05:39

Update

$Sage Therapeutics (SAGE.US)$ Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint

_easymoneysniper_

Jun 11 06:16

$Sage Therapeutics (SAGE.US)$ what just happened